Monday, February 24, 2025 | 04:38 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Zydus Cadila sees 60% of topline from US by FY20 even as rivals lose share

Company has already received highest number of USFDA approvals since April 2017 and aims to launch 75% of these

Cadila Healthcare
Premium

Sohini Das Ahmedabad
Cadila Healthcare is having a dream run in the US, riding primarily on growth in base business coupled with a steady pipeline of launches lined up for that country. The contribution of the US in its overall turnover has been growing steadily at a time when most of its peers saw the share of US business shrink in their turnovers -- it grew from 43 per cent in the first quarter of the 2017-18 fiscal to 48 per cent now. The company expects the contribution of US to rise to 60 per cent of its turnover by 2019-20.

This

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in